NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
-
Clinical Trial Information
Trial Contact: Spinelli, Jennifer; Armatti, Julie M; Doyle, Katherine M; Parker, Melanie
Trial Phone: 321.841.5357 ; 321-843-5284 ; 3218412008 ; 321-843-1036
-
IRB No: APEC1621
Protocol Abbrev: APEC1621
Principal Investigator: Amy A. Smith, MD
Phase: Drug: Phase II
Age Group: Pediatric
Secondary Protocol No: APEC1621
Treatment: olaparib, vemurafenib, ensartinib, selumetinib sulfate, PI3K/mTOR Inhibitor LY3023414, Tazemetostat, Erdafitinib, Larotrectinib, palbociclib, Ulixertinib, Ivosidenib, Zamestra
Therapies Involved: Chemotherapy
ClinicalTrials.gov ID: NCT03155620
-
Objective
This screening and multi-sub-study phase II trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and/or for which no standard treatment exists that has been shown to prolong survival.
-
Key Eligibility
Ages Eligible for Study: 12 Months to 21 Years (Child, Adult)
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
